OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Artificial intelligence in drug discovery: recent advances and future perspectives	194
What is the current value of MM/PBSA and MM/GBSA methods in drug discovery?	117
The importance of sulfur-containing motifs in drug design and discovery	105
Artificial intelligence, machine learning, and drug repurposing in cancer	86
Artificial intelligence in early drug discovery enabling precision medicine	62
How do we address neglected sulfur pharmacophores in drug discovery?	61
Strategies for targeting undruggable targets	52
An overview of rational design of mRNA-based therapeutics and vaccines	50
How necessary are animal models for modern drug discovery?	50
Knowledge graphs and their applications in drug discovery	47
An update on the importance of plasma protein binding in drug discovery and development	43
The 1,2,3-triazole ‘all-in-one’ ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool	40
Discovery of CFTR modulators for the treatment of cystic fibrosis	40
Assigning confidence to molecular property prediction	39
Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery	39
Electrophilic warheads in covalent drug discovery: an overview	38
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?	35
Frontiers of metal-coordinating drug design	34
Critical assessment of AI in drug discovery	33
Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents	33
Evolution of the drug-target residence time model	32
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials	32
Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?	31
The latest automated docking technologies for novel drug discovery	30
Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis	30

Multi-objective optimization methods in novel drug design	30
Advances in biocatalytic and chemoenzymatic synthesis of nucleoside analogues	29
Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?	28